An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00454558 |
|
Recruitment Status :
Completed
First Posted : March 30, 2007
Last Update Posted : October 16, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This is a study to demonstrate the feasibility of an individual dose titration scheme based on the systolic blood pressure with a dose range from 1.0 mg TID to 2.5 mg TID. Patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH) will be included. After diagnosis by an expert center, patients receive medication three times a day starting with 1.0 mg TID. The first tablets are given in the hospital, then the patients are allowed to go home and take the medication at home. After 2 weeks, patients return to the hospital for an ambulatory visit and the dose may be increased based on the actual condition of the patient (blood pressure and adverse events). Several measurements will be performed to test the efficacy of the drug and whether there are any unwanted reactions to the drug (blood tests, ECG, 6 minute walk test, imaging by Echo, quality of life scores). The dose of the drug will then be increased further until unwanted effects may occur or the blood pressure drops to low. The highest dose tested will be 2.5 mg TID. After 12 weeks the patient is going to stay in the hospital again and a right heart catheter is performed to examine the changes in hemodynamics after 12 weeks of treatment with the drug. If the patients give their consent they can enter a long-term extension trial continuing on BAY63-2521 with the dose reached after 12 weeks. Every 3 months an ambulatory visit at the specialist center will be performed including measurements of safety (blood tests, ECG, clinical assessment) and efficacy (6 minute walk test, Borg dyspnea scale, NT-pro BNP). Blood tests and ECG have been removed begin of 2013 as safety parameter by amendment 7; furthermore Borg dyspnea score and NT-proBNP have been removed as efficacy parameter.
Initially the inclusion of ten patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH) was planned. Later on the patient number was amended and 75 patients entered the trial.
Furthermore the trial duration was extended and a long term treatment with BAY63-2521 was offered to the patients. Finally 68 patients moved over to the long term extension period of the trial.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Hypertension, Pulmonary | Drug: Riociguat (Adempas, BAY63-2521) | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 75 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Multicenter, Non-randomized, Non-blinded, Noncontrolled Study to Investigate the Impact of Multiple Doses of BAY 63-2521 on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Pulmonary Hypertension in a 12-week 3 Times a Day Individual Dose Titration Scheme |
| Study Start Date : | January 2007 |
| Actual Primary Completion Date : | July 2014 |
| Actual Study Completion Date : | September 2014 |
| Arm | Intervention/treatment |
|---|---|
| Experimental: Arm 1 |
Drug: Riociguat (Adempas, BAY63-2521)
Biweekly uptitration of BAY63-2521 (Oral sGC Stimulator) starting from 1.0 mg TID up to 2.5 mg TID in steps of +0.5 mg according to safety and tolerability. |
- To investigate the safety, tolerability and feasibility of individual titration of BAY63-2521 according to peripheral systolic blood pressure [ Time Frame: 3 months ]
- To investigate the long term safety and tolerability of BAY63-2521 [ Time Frame: max. 84 months ]
- 6MWT [ Time Frame: max. 84 months ]
- Right heart catheter invasive hemodynamics [ Time Frame: 3 months ]
- WHO functional class assessment [ Time Frame: max. 84 months ]
- NT-pro BNP [ Time Frame: 75 months ]
- Imaging by echo [ Time Frame: 3 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with CTEPH or PAH in NYHA class II or III
Exclusion Criteria:
- Patients with PDE 5 inhibitor or prostacycline pretreatment, relevant pulmonary diseases, relevant cardiac diseases, severe coagulation disorders, moderate to severe hepatic or renal insufficiency, pregnancy, hypotension
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00454558
| Germany | |
| Heidelberg, Baden-Württemberg, Germany, 69120 | |
| Löwenstein, Baden-Württemberg, Germany, 74245 | |
| München, Bayern, Germany, 81377 | |
| Regensburg, Bayern, Germany, 93042 | |
| Bad Nauheim, Hessen, Germany, 61231 | |
| Gießen, Hessen, Germany, 35392 | |
| Greifswald, Mecklenburg-Vorpommern, Germany, 17475 | |
| Hannover, Niedersachsen, Germany, 30625 | |
| Köln, Nordrhein-Westfalen, Germany, 50924 | |
| Homburg, Saarland, Germany, 66421 | |
| Halle, Sachsen-Anhalt, Germany, 06120 | |
| Dresden, Sachsen, Germany, 01307 | |
| Leipzig, Sachsen, Germany, 04103 | |
| Berlin, Germany, 12559 | |
| Hamburg, Germany, 20246 | |
| Study Director: | Bayer Study Director | Bayer |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Bayer |
| ClinicalTrials.gov Identifier: | NCT00454558 |
| Other Study ID Numbers: |
12166 2006-003520-10 ( EudraCT Number ) |
| First Posted: | March 30, 2007 Key Record Dates |
| Last Update Posted: | October 16, 2015 |
| Last Verified: | September 2015 |
|
Pulmonary Arterial Hypertension (PAH) Chronic Thromboembolic Pulmonary Hypertension (CTEPH) |
|
Hypertension, Pulmonary Hypertension Vascular Diseases Cardiovascular Diseases Lung Diseases |
Respiratory Tract Diseases Riociguat Enzyme Activators Molecular Mechanisms of Pharmacological Action |